Definitive Statement Filed for Reverse Merger, 97% Dilution for Existing Shareholders

summarizeSummary

This definitive information statement finalizes the terms of the previously announced reverse merger, which is a critical, thesis-altering event for EKSO Bionics shareholders. The transaction effectively transforms the company from a medical device firm into an AI/cloud services provider, "ChronoScale Corporation," with existing shareholders retaining only a minimal stake (approximately 3%) in the combined entity. While the $15 million equity financing and the strategic pivot offer a lifeline to a company that previously disclosed a "going concern" warning, the terms represent a near-complete transfer of ownership and control. Investors should understand that their investment thesis in EKSO Bionics' original business is fundamentally altered, and their ownership will be severely diluted in the new, much larger, and differently focused company. The new board will be controlled by the acquiring entity, signaling a complete change in corporate governance and strategic direction.

check_boxKey Events

• Reverse Merger Finalized

  EKSO Bionics will acquire Applied Digital Cloud Corporation, with existing EKSO shareholders retaining approximately 3% ownership in the combined entity, ChronoScale Corporation. This follows the preliminary PRER14C filings on March 30, 2026, and April 3, 2026.

• Massive Shareholder Dilution

  The transaction will result in approximately 97% dilution for current EKSO shareholders, as the acquirer and its parent will collectively own 97% of the combined company.

• Strategic Business Pivot

  The company will transition from its medical device business to an AI/cloud services platform, operating under the new name "ChronoScale Corporation." This pivot addresses the 'going concern' warning disclosed in the company's last 10-K filing on February 23, 2026.

• Capital Infusion & Authorized Share Increase

  The merger includes a $15 million equity financing from Applied Parent and an increase in authorized common stock from 141,428,571 to 290,000,000 shares to facilitate the merger and future equity plans.

auto_awesomeAnalysis

This definitive information statement finalizes the terms of the previously announced reverse merger, which is a critical, thesis-altering event for EKSO Bionics shareholders. The transaction effectively transforms the company from a medical device firm into an AI/cloud services provider, "ChronoScale Corporation," with existing shareholders retaining only a minimal stake (approximately 3%) in the combined entity. While the $15 million equity financing and the strategic pivot offer a lifeline to a company that previously disclosed a "going concern" warning, the terms represent a near-complete transfer of ownership and control. Investors should understand that their investment thesis in EKSO Bionics' original business is fundamentally altered, and their ownership will be severely diluted in the new, much larger, and differently focused company. The new board will be controlled by the acquiring entity, signaling a complete change in corporate governance and strategic direction.